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Abstract
Background
Helminths can modulate the host immune response to Plasmodium falciparum and can
therefore affect the risk of clinical malaria. We assessed here the effect of helminth infec-
tions on both the immunogenicity and efficacy of the GMZ2 malaria vaccine candidate, a
recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual
blood-stage antigens of P. falciparum. Controlled human malaria infection (CHMI) was used
to assess the efficacy of the vaccine.
Methodology
In a randomized, double-blind Phase I clinical trial, fifty, healthy, lifelong malaria-exposed
adult volunteers received three doses of GMZ2 adjuvanted with either Cationic Adjuvant
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Production of PfSPZ Challenge (NF54) by Sanaria
was supported in part by the National Institute of
Allergy and Infectious Diseases of the National
Formulation (CAF) 01 or Alhydrogel, or a control vaccine (Rabies) on days (D) 0, D28 and
D56, followed by direct venous inoculation (DVI) of 3,200 P. falciparum sporozoites (PfSPZ
Challenge) approximately 13 weeks after last vaccination to assess vaccine efficacy. Partici-
pants were followed-up on a daily basis with clinical examinations and thick blood smears to
monitor P. falciparum parasitemia for 35 days. Malaria was defined as the presence of P. fal-
ciparum parasites in the blood associated with at least one symptom that can be associated
to malaria over 35 days following DVI of PfSPZ Challenge. Soil-transmitted helminth (STH)
infection was assessed by microscopy and by polymerase chain reaction (PCR) on stool,
and Schistosoma infection was assessed by microscopy on urine. Participants were consid-
ered as infected if positive for any helminth either by PCR and/or microscopy at D0 and/or at
D84 (Helm+) and were classified as mono-infection or co-infection. Total vaccine-specific
IgG concentrations assessed on D84 were analysed as immunogenicity outcome.
Main findings
The helminth in mono-infection, particularly Schistosoma haematobium and STH were sig-
nificantly associated with earlier malaria episodes following CHMI, while no association was
found in case of coinfection. In further analyses, the anti-GMZ2 IgG concentration on D84
was significantly higher in the S. haematobium-infected and significantly lower in the Stron-
gyloides stercoralis-infected groups, compared to helminth-negative volunteers. Interesting,
in the absence of helminth infection, a high anti-GMZ2 IgG concentration on D84 was signifi-
cantly associated with protection against malaria.
Conclusions
Our results suggest that helminth infection may reduce naturally acquired and vaccine-
induced protection against malaria. Vaccine-specific antibody concentrations on D84 may
be associated with protection in participants with no helminth infection. These results sug-
gest that helminth infection affect malaria vaccine immunogenicity and efficacy in helminth
endemic countries.
Author summary
Helminths, mainly because of their immune regulatory effects, are able to impact the
response induced by vaccines. In the context of clinical trial designs that measure accrual
of natural infections during follow up or outcome of controlled human malaria infection
(CHMI), their effect on vaccine efficacy can be measured. Indeed, most of such clinical
trials on malaria vaccine candidates conducted in Africa, especially where the prevalence
of helminths is high, have shown a certain limit in their efficacy and immunogenicity, as
compared to results observed in European and U.S volunteers. The present analysis
assessed the effect of helminths on GMZ2, a malaria vaccine candidate. We found a high
level of anti-GMZ2 antibodies among volunteers not infected with helminths and pro-
tected against CHMI, indicating efficacy of the candidate vaccine in this population. We
found a species-dependent effect of helminths on the level of post-immunization GMZ2-
specific IgG concentration, and an association of helminths with an early onset of malaria
in CHMI. Our findings reveal that helminths are associated with immunogenicity and
may decrease the protective effect of antibodies induced by vaccination. Helminth
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infection status shall be determined when measuring the immunogenicity and efficacy of
malaria vaccine candidates in helminth endemic countries.
Introduction
Helminth infections remain widespread and cause important neglected tropical diseases. The
clinical presentations include anemia, malnutrition, developmental deficiencies causing signifi-
cant morbidity and mortality [1]. Blood flukes like Schistosoma haematobium and the group of
soil-transmitted helminths (STH) including Ascaris lumbricoides, hookworm, Trichuris trichiura
and Strongyloides stercoralis are most prevalent in developing countries, particularly in sub-Saha-
ran Africa [2], where malaria endemicity is high. In areas of co-endemicity, individuals fre-
quently harbour these infections concomitantly. Several studies have already highlighted the role
of helminth infections on the modulation of immune responses directed against Plasmodium fal-
ciparum antigens or against vaccine antigens, although with contradictory findings. Some studies
reported a down-modulating effect of S. haematobium infection on anti-P. falciparum immune
responses such as negative association between the intensity of S. haematobium infection and
IgG1, IgG3 and IgG4 antibody subclass levels directed to malarial total schizont extract [3]. S.
haematobium infection has also been shown to affect specific IgG1 directed to P. falciparum (Pf)
MSP1 and GLURP [4], or to affect the anti-Pfs48/45 IgG level [5]. By contrast, other studies have
reported protection against malaria due to a Th2-enriched environment associated with S. hae-
matobium infection [6], or anti-malarial protective antibody responses favored by S. haemato-
bium-P. falciparum coinfection [7]. With regard to STH infection, some authors have reported
an association with an increased risk of clinical malaria [8] while other studies ruled out an effect
of these helminth infections on the course of Plasmodium infection [9,10]. A recent study carried
out on school-age children in rural area of Gabon showed an increased risk of P. falciparum
infection due to STH in schistosomiasis-positive children [11]. Many studies have also been con-
ducted to assess the effect of helminth infection on several commonly used vaccines [12–18], but
little is known about their interaction with malaria vaccine candidates [19–22].
GMZ2, a malaria vaccine candidate, is a recombinant fusion protein with fragments of P.
falciparum GLURP and MSP3 [23] that showed good immunogenicity when formulated with
aluminum hydroxide (alum) [24–26] or Cationic Adjuvant Formulation 01 (CAF01) adjuvant
[27]. Importantly, pre-school aged children vaccinated with GMZ2-alum and infected with T.
trichiura had low vaccine-specific IgG responses compared to their non-infected counterparts
or those infected with A. lumbricoides [20]. That study clearly suggested that helminth infec-
tions affected GMZ2 vaccination-induced responses. We therefore hypothesized that helminth
infection would negatively affect the immunogenicity and efficacy of GMZ2. Our study
focused on S. haematobium mainly. Indeed, the study area is endemic for S. haematobium
[5,11,28,29], although S. mansoni infections may also rarely occur [30]. In the present explor-
atory analysis, our main objective was to assess the effect of S. haematobium and STH on the
time of the occurrence of malaria episodes after CHMI. In addition to that, we also assessed
the effect of that helminth on the immunogenicity and the efficacy of GMZ2 when adjuvanted
with either CAF01 or alum in Gabonese adults.
Methods
Ethics statement
The original study was approved by the Comité National d’Ethique de la Recherche of Gabon,
under the reference N˚004/2015/SG/P. The trial was performed according to the International
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Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
Good Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent
was obtained from all participants included in the study.
Study area
The original study was conducted at the Centre de Recherches Médicales de Lambaréné (CER-
MEL), Gabon (April 2015 –November 2015). Lambaréné is a semi-urban town, an area in
which malaria [31] and other parasitic infections particularly S. haematobium and STH [28]
are endemic.
Study design
The detailed design of the main study is described elsewhere [27]. Briefly, eligible participants
were randomized to receive three doses, 4-weeks apart (Day 0, Day 28, Day 56) of either 30μg
or 100μg of GMZ2-CAF01, 100μg GMZ2-Alhydrogel (alum), or control rabies vaccine (Ver-
orab, Sanofi Pasteur). Vaccine efficacy was assessed using standardized controlled human
malaria infection (CHMI) by direct venous inoculation (DVI) of aseptic, purified, cryopre-
served 3,200 P. falciparum sporozoites (PfSPZ Challenge, Sanaria Inc.) approximately 13
weeks after the last immunization (on Day 56), and participants were followed-up on a daily
basis with clinical and parasitological (thick blood smears for malaria) examinations for 35
days (S1 Fig). Malaria was defined as the presence of P. falciparum parasites associated with at
least one malaria-attributable symptom over 35 days following DVI of PfSPZ Challenge. Typi-
cal malaria symptoms include fever, tachycardia, chills, rigor, sweats, headache, anorexia, nau-
sea, vomiting, myalgia, arthralgia, chest pain, low back pain, abdominal pain and fatigue.
CHMI results in 34 volunteers showed that five participants were fully protected (no parasitae-
mia and no malaria symptoms), fourteen controlled parasitaemia (low oscillating parasitemia
and no symptoms) and fifteen had developed malaria (monotone increase of parasitemia with
symptoms). The proportion of participants who developed malaria and the time to develop
malaria were similar in all vaccinated groups [27]. Participants were treated immediately when
they met the malaria case definition. For participants without malaria, follow-up was censored
at 35 days after PfSPZ Challenge inoculation (C+35) and treatment was administered irrespec-
tive of malaria status on that day. P. falciparum infection was treated with artemether-lumefan-
trine as the first line treatment. Urine samples were collected at D0 and at D84 on three
consecutive days whereas stool samples were collected once at D0 and once at D84 (S1 Fig).
Urine and stool were examined for the presence of Schistosoma eggs and STH eggs or larvae,
respectively. An aliquot of samples was frozen for DNA extraction and was processed after
D84. Participants were considered as helminth infected if found positive on D0 and/or on D84
by any helminth species. All infected participants detected by microscopy were treated for hel-
minth infection after D84 according to local guidelines.
Laboratory analysis
GMZ2-specific IgG concentration measurements. Specific anti-GMZ2 IgG as well as
those directed to MSP3 and GLURP were assessed in sera by Enzyme Linked ImmunoSorbent
assay (ELISA), as described elsewhere [27]. Briefly, the micro titration plates (Nunc) were
coated with 100 μl of GMZ2, 100 μl of GLURP or 100 μl of MSP3 diluted in PBS, and plates
were covered and incubated overnight at 4˚C. Following plates washing, 150 μl of the blocking
solution were added in each well and plates were incubated for 1 hour at room temperature.
The plates were washed and the diluted serum samples were added in each well plate, followed
by incubation for 2 hours at room temperature. After washing, the plates were incubated with
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100 μl of peroxidase-conjugated goat anti-human IgG diluted to 1/65000 with the dilution
solution, then incubated for 1 hour at room temperature. The plates were washed and 100 μl
of the color solution (TMB One) were added, incubated for 20 min at temperature room in the
dark, followed by addition of 100 μl of 0.2M sulfuric acid. The plates were immediately read at
an absorbance of 450 nm and a reference at 620 nm using a microplate reader (Thermo Mul-
tiskan, Model 355).
Helminth detection by microscopy
The Kato Katz enrichment and microscopy was used to detect eggs of hookworms, A. lumbri-
coides, and T. trichiura in stool samples, and coproculture was performed to detect larvae of
hookworms and S. stercoralis as described elsewhere [28,32,33]. Urine (around 10 mL) filtra-
tion followed by microscopy was used to detect the presence of S. haematobium eggs in urine
[29]. Presence of microfilariae of Loa loa and Mansonella perstans in blood was assessed using
the leuco-concentration technique [34].
DNA extraction, amplification, and detection
Parasite DNA from stool. DNA extraction, amplification, and detection Parasite DNA
from stool was isolated and amplified following procedures previously described with minor
modifications [35–37]. For the isolation of DNA, 100 mg of stool was suspended in 200 μL of
phosphate-buffered saline (Sigma-Aldrich) with 2% polyvinylpolypyrolidone (Sigma-Aldrich)
[36], followed by homogenization and bead-beating performed in a 2 ml tube containing Lys-
ing Matrix E (MP Biomedicals). Suspended feces were frozen at -70˚C for 30 min. After thaw-
ing, suspensions were treated with sodium dodecyl sulphate-proteinase K for 2 h at 55˚C [37]
and DNA was extracted with the QIAamp DNA mini kit (QIAgen) according to the manufac-
turer’s instruction. During the isolation an internal extraction control, 103 PFU/ml phocine
herpes virus 1 (PhHV-1) was added within the isolation lysis buffer in each sample [37]. Previ-
ously described PCR primer and probe sequences [38,39] were used for the amplification of A.
lumbricoides, S. stercoralis, Necator americanus and T. trichiura. Those species were the most
detected by microscopy in our study and are known to be most prevalent in the study area
[40]. Primer and probe concentrations were optimized for the assay (S1 and S2 Tables). Ampli-
fication conditions were 15 min at 95˚C followed by 45 cycles of 15 s at 95˚C, 30 s at 60˚C and
30 s at 72˚C respectively. Amplification and detection of fluorescence was done on a LightCy-
cler 480 (Roche) machine. Cq values� 39 were considered as positive. No DNA extraction
was done on urine samples.
Statistical analyses
Data were exported in R version 3.4.2 for statistical analysis. Graphs were made using Graph-
Pad Prism Version 6 and R. Study participants were divided in two main groups; those found
to be uninfected with helminths by both qPCR and microscopy formed the helminth negative
(Helm-) group, and those shown to be infected with helminths either by qPCR and/or by
microscopy formed the helminth positive (Helm+) group. In order to assess the effect of indi-
vidual helminth species, subgroups were formed based on the respective mono-infections i.e.
S. haematobium (Sh+) and S. stercoralis (Str+). Due to the very low number of cases, and as no
considerable difference in concentration of anti-GMZ2 antibodies was found between these
both STH, T. trichiura and hookworm infections were merged into the third Tt+/Hw+ sub-
study group. The remaining study participants constituted the coinfection (CoInf+) sub-study
group as they were infected with more than one parasite. The Mann-Whitney non-parametric
test was used to compare characteristics and the haematological profiles of the study
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population, while linear regression was used for univariable and multivariable analyses to com-
pare specific IgG levels between study groups, using baseline vaccine-specific total IgG concen-
tration as variable of adjustment. The unpaired t test was performed to compare the specific
IgG concentration between each combination of two groups after stratification of the helminth
infected group, following by ANOVA test with Holm-Sidak’s multiple comparisons. A
Kaplan-Meier curve and Log-rank tests were used to assess the time to malaria episodes
between study groups and subgroups. All analyses were considered exploratory. The tests were
considered statistically significant for a p-value less than 0.05.
Results
Participants flow and characteristics of the study population
Of the forty-five (45) participants from the fifty (50) included in the clinical trial and for whom
all data are available, five (5) were excluded from analysis as they received the control vaccine
(Verorab) and one further patient was excluded due to missing data for the PCR on stool sam-
ples for STH detection. Data on thirty-nine participants are therefore considered for analysis
(Fig 1). Of them, thirteen (13) were infected with at least one STH species (Hookworm, A.
lumbricoides, T. trichiura, S. stercoralis) as determined by the presence of eggs or larvae in
stool using microscopy, while twenty-six (26) were considered uninfected. Using the PCR
method, a total of nineteen (19) participants were found to be infected with at least one species
of STH, including 6 of those for whom microscopy was negative, while the twenty (20) other
participants were uninfected (Fig 1).
Assessing participants’ schistosomiasis status using urine filtration, a total of fourteen (14)
participants had Schistosoma eggs in urine, including ten (10) participants also infected with
STH using microscopy and/or PCR, and twenty-five (25) participants had no Schistosoma
eggs, including nine (9) participants infected with STH using microscopy and/or PCR. No
Schistosoma eggs were found in stool samples, and no filarial infection was detected in the
study population. In summary, 16 (41%) participants were classified as uninfected (Helm-),
and 23 (59%) were classified as infected (Helm+) (Fig 1).
Among the participants included in the Helm+ group, 4 had S. haematobium alone, 4 had
S. stercoralis, 2 had T. trichiura and 1 had hookworm. As detailed in S3 Table, 12 participants
were infected with more than one helminth species and were included in a CoInf group, with
S. haematobium being the most prevalent species (34%), followed by T. trichiura (28%), Hook-
worm (21%), S. stercoralis (10%) and A. lumbricoides (7%), respectively. All 39 participants
included in this analysis were men with a median age (interquartile range) of 23 (5.5) years.
Compared to the Helm- group, the hemoglobin level was lower in the Helm+ group (p-value =
0.02) while the levels of white blood cells (p-value = 0.0008), lymphocytes (p-value = 0.001),
eosinophils (p-value = 0.0006) and basophils (p-value = 0.001) were increased (Table 1).
Helminth infection and vaccine-specific IgG concentration
As shown elsewhere [27] and confirmed here, immunization with GMZ2 induced a high levels
of anti-GMZ2, anti-MSP3 and anti-GLURP IgG antibodies. The differences in antibody levels
between D0 and D84 are presented in S2 Fig. Here, we compared the antibody concentration
on D84 between Helm- and Helm+ groups, as well as with infected subgroups. No statistically
significant relationship was observed between helminth status and level of anti-GMZ2 IgG
(p-value = 0.49), anti-MSP3 (p-value = 0.18) and anti-GLURP IgG (p-value = 0.30) concentra-
tion (Fig 2A–2C). No significant relationship was observed when applying multivariate
analyses.
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As presented in Table 2, we found at univariate analysis no relationship between helminths
status and the level of the three antibody concentrations measured and this in the three vaccine
groups.
Fig 1. Flow chart of the study participants. PCR: Polymerase chain reaction STH: Soil-transmitted helminth SH: Schistosoma haematobium
N = number
https://doi.org/10.1371/journal.pntd.0009361.g001
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Considering the sub-study groups, we found a relationship between S. haematobium status
(p-value = 0.01), S. stercoralis (p-value = 0.03) status and vaccine-specific IgG concentration
on D84. Compared to anti-GMZ2 IgG concentration on D84 in those uninfected (mean log
concentration ±SD: 3.49 ±0.14), participants infected with S. haematobium alone presented a
higher level of anti-GMZ2 IgG (3.69 ±0.10), while those infected with S. stercoralis alone had
lower anti-GMZ2 IgG levels (3.32 ±0.19) (Fig 3A). Additionally, a significantly lower level of
anti-GMZ2 IgG was observed in Str+ individuals compared with the Sh+ individuals (p-value
= 0.0008), Tt+/Hw+ individuals (3.62 ±0.16, p-value = 0.003) and CoInf+ individuals (3.49
±0.17, p-value = 0.03) (Fig 3A). No significant differences between the groups were observed
when applying a correction for multiple comparison. In addition, no relationships were
observed for either anti-MSP3 or anti-GLURP IgG levels and helminth status (Fig 3B and 3C).
Table 1. Characteristics and hematological profile of the study population on D84 with regard to helminth status.
Helminth negative Helminth positive p-value�
N (%) 16 (41) 23 (59) -
Age (years) 25 (10) 22 (4) 0.06
BMI (kg/m2) 22.40 (3.05) 22.50 (2.5) 0.79
Hb (g/dL) 14.7 (1.4) 13.6 (1.6) 0.02
WBC (x103/mm3) 4.25 (1.37) 5.70 (1.55) 0.0008
Lymphocytes (x103/mm3) 2.01 (0.49) 2.42 (0.68) 0.001
Neutrophils (x103/mm3) 1.97 (1.18) 2.62 (1.76) 0.05
Eosinophils (x103/mm3) 0.07 (1.18) 0.33 (0.82) 0.0006
Basophils (x103/mm3) 0.04 (0.03) 0.06 (0.04) 0.001
BMI = Body mass index, Hb = Hemoglobin, WBC = White blood cells.
� Mann-Whitney test. Data are median (interquartile range)
https://doi.org/10.1371/journal.pntd.0009361.t001
Fig 2. Post immunization antibody concentration at D84 in helminth uninfected and infected groups (Helm- and Helm+). Fig 2 illustrates the log of
GMZ2-specific (A), MSP3-specific (B), GLURP-specific (C) IgG concentration at D84 in helminth negative (Helm-, n = 16) and helminth positive (Helm+,
n = 23) groups. Comparisons were performed by univariate and multivariate linear regression adjusted for baseline data as independent covariable. The graphs
are mean ± standard deviation. Statistical significance was set for p value below 0.05. �p<0.05, ��p<0.01, ���p<0.001, ����p<0.0001. NS = Non-significant.
https://doi.org/10.1371/journal.pntd.0009361.g002
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Helminth status and protection from malaria
Assessing the time to the occurrence of malaria episodes after CHMI between helminth
groups, we found a relationship between any helminth infection and time to develop malaria
(Log-Rank test: p-value = 0.039), as depicted in Fig 4A, such that those with helminth infection
developed malaria significantly earlier than those without. When considering the infected sub-
groups, S. haematobium (Log-Rank test: p-value = 0.008) and STH (Log-Rank test: p-value =
0.037) infections were associated with faster times to malaria (Fig 4B and 4C). No statistically
significant difference was observed between coinfection status and time to develop malaria
(Log-Rank test: p-value = 0.19, Fig 4D).
The proportion of participants who did not develop malaria after CHMI is presented for
Helm- (8/11, 72.7%) and Helm+ (7/16, 43.8%) groups (A), for Helm- and Sh+ (1/3, 33.3%)
(B), for Helm- and Sth+ (1/3, 33.3%) (C), and in Helm- and CoInf+ (5/10, 50%) (D).
In additional analyses in the helminth coinfected group assessing the distribution of hel-
minths species between malaria outcome groups following CHMI, the results showed that the
distribution of helminth species was different between participants who did and those who did
not develop malaria (S4 Table).
Table 2. Comparison of antibody log concentrations mean (±SD) between helminth infection groups at D84 stratified by study vaccination groups.
100μg GMZ2-Alum 30μg GMZ2-CAF01 100μg GMZ2-CAF01
Helm- (n = 07) Helm+ (n = 04) p-value Helm- (n = 03) Helm+ (n = 05) p-value Helm- (n = 06) Helm+ (n = 14) p-value
Anti-GMZ2 IgG 3.47 (±0.15) 3.64 (±0.11) 0.09 3.51 (±0.14) 3.53 (±0.22) 0.90 3.50 (±0.13) 3.47 (±0.20) 0.70
Anti-MSP3 IgG 3.52 (±0.45) 3.34 (±0.36) 0.52 3.60 (±0.65) 3.19 (±0.25) 0.23 3.32 (±0.38) 3.51 (±0.38) 0.30
Anti-GLURP IgG 3.52 (±0.16) 353 (±0.11) 0.91 3.39 (±0.27) 3.46 (±0.29) 0.73 3.64 (±0.16) 3.66 (±0.25) 0.88
Helm+ = positive for helminth infection
Helm- = negative for helminth infection
https://doi.org/10.1371/journal.pntd.0009361.t002
Fig 3. Post immunization antibody concentration at D84 in Helm- and Helm+ subgroups. Fig 3 illustrates the log of specific-GMZ2 (A), specific-MSP3 (B),
specific GLURP (C) IgG concentration at D84 in Helm- and mono-infected by Schistosoma haematobium (Sh+, n = 4), those mono-infected with Strongyloides (Str
+, n = 4), those mono-infected with Trichuris trichiura or hookworm (Tt+/Hw+, n = 3), and those coinfected by at least two different helminths (Coinf+, n = 12).
The comparison was performed by multivariate linear regression adjusted for baseline vaccine-specific total IgG concentration as independent covariable. The
graphs show mean ± standard deviation. Statistical significance was set for p value below 0.05 and is indicated when statistically significant. �p<0.05, ��p<0.01,
���p<0.001. NS = Non-significant.
https://doi.org/10.1371/journal.pntd.0009361.g003
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Vaccine-specific IgG level and CHMI outcome according to helminth
status
As mentioned elsewhere [27], and confirmed here (Fig 5A), no difference was found between
vaccine-specific IgG concentration on D84 and protection against clinical malaria following
CHMI. We therefore assessed whether this observation differed according to helminth infec-
tion status. In a stratified analysis, a relationship was found between the occurrence of clinical
malaria after CHMI and the anti-GMZ2 IgG concentration (p-value = 0.048) on D84 in the
Helm- group. The anti-GMZ2 IgG concentration was higher among those who did not
Fig 4. Time to occurrence of malaria episodes after CHMI.
https://doi.org/10.1371/journal.pntd.0009361.g004
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experience malaria (3.51 ±0.13) compared to those who experienced malaria (3.32 ±0.0.6,
Fig 5B), although the increase was not statistically significant when adjusted with baseline anti-
GMZ2 IgG concentration. In the Helm+ group, no such relationship was found (p-value =
0.51, Fig 5C).
Discussion
The results of the study presented here show that helminth species can differentially affect the
specific immune response following administration of a malaria vaccine candidate: partici-
pants infected with S. haematobium had higher GMZ2-specific IgG on D84 post-first immuni-
zation, while S. stercoralis infection was associated with a lower IgG response on D84
compared to that of helminth uninfected participants.
From our analysis, in comparison to helminth uninfected individuals, S. haematobium
infection was associated with a higher post-immunization anti-GMZ2 IgG response. It has
been shown that S. haematobium infection is associated with an increased systemic concentra-
tion of the C3d molecule of the complement system [41], which can enhance B cell signaling
[42]. We speculate that this or a similar adjuvant-like phenomenon may explain our findings.
Moreover, S. haematobium could augment antibody production by influencing the biological
environment through enhanced IL-4 production [6], favoring antimalarial antibody produc-
tion [43]. It should be noted that S. haematobium infection had no significant effect on the
antibody responses directed to either MSP3 or GLURP, the two antigens combined in GMZ2,
in contrast to the findings of a recent study [44], although the level of anti-GLURP IgG con-
centration was indeed higher in S. haematobium infected compared to uninfected individuals,
Fig 5. Anti-GMZ2 IgG concentration and CHMI outcome groups according to helminth status Comparison of vaccine-specific total IgG concentration
at D84 between those having clinical malaria (monotone increase of parasitemia with symptoms) and those without clinical malaria (low oscillating
parasitemia and no symptoms (control) and those with no parasitemia and no symptoms (protected)) after the CHMI was performed in all participants
(n = 12 vs 14, 5A), in helminth uninfected (n = 3 vs 8, 5B), and infected (n = 9 vs 7, 5C) participants. The comparison was done by multivariate linear
regression using baseline vaccine-specific total IgG concentration as variable of adjustment. Statistical significance was set for p value below 0.05. �p<0.05
NS = Non-significant.
https://doi.org/10.1371/journal.pntd.0009361.g005
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but this difference was not statistically significant. It is well known that MSP3 constitutes a less
immunogenic component of GMZ2 [24,25], possibly explaining this observation. The inten-
sity of S. haematobium infection may have a determining role in its effect on other parasites. In
our study cohort, the S. haematobium egg count in infected participants was low (S5 Table),
possibly explaining the absence of any deleterious effect on the immunogenicity of GMZ2.
In contrast to our observations in S. haematobium-infected individuals, we observed low
post-immunization anti-GMZ2 IgG levels in S. stercoralis-infected participants compared to
post-immunization anti-GMZ2 IgG concentration in the helminth uninfected group. S. ster-
coralis has been shown to reduce B cell numbers, and to affect B cell responses during latent
tuberculosis infection [45]. S. stercoralis can also reduce the induction of mycobacterial-spe-
cific IgM and IgG responses and the expression levels of the B-cell growth factors APRIL and
BAFF [45]. There is virtually no data on the effect of this parasite on the immunogenicity of
malaria vaccine antigens. In the present study, we show that this STH can negatively affect the
vaccine IgG concentration as we have shown in a recent study conducted in children. We
hypothesize that the presence of S. stercoralis in our study population could considerably
inhibit B cell activity, via, for example, the induction of specific regulatory mechanisms includ-
ing Treg [46].
In our study, co-infected participants had a similar specific IgG concentration compared to
those uninfected, indicating potentially opposing effects of different species, possibly explain-
ing the lower concentration of anti-GMZ2 IgG in the co-infected group compared to those
harbouring S. haematobium alone; the question thus arises as to the importance of considering
the effect of every single species of helminths separately on GMZ2 immunogenicity. Indeed,
Esen and colleagues showed that infection with T. trichiura affects the concentration of anti-
GMZ2 IgG in children, whilst infection with A. lumbricoides had no such effect [20], strongly
suggesting a species-dependent effect.
Investigating the delay to development of malaria episodes with regard to helminth status,
we observed that volunteers infected with helminths, irrespective of the species, develop
malaria episodes earlier than those without these infections, possibly essentially due to S. hae-
matobium and STH. Such an effect of S. haematobium and STH has been observed in the same
area in young children [11], suggesting that helminths could affect malaria vaccine efficacy in
adults through various mechanisms neither well known nor well described. We hypothesize
that this effect is helminth species dependent. However, given the relatively small number of
helminth mono-infected volunteers and the comparatively higher number of coinfected vol-
unteers we had, it is difficult to elucidate any one infection’s role on susceptibility to malaria.
Indeed, the absence of such an effect in co-infected volunteers supports the idea of opposing
effects of these different helminth species, although the differences observed in the proportions
of different helminths species between those who did and did not developed malaria after
CHMI in the helminth coinfected could also explain the fact.
We found that those with no helminth infection who had a higher vaccine-specific IgG
response on D84 were protected against clinical malaria. Antibodies are known to play an
important role in acquired protective immunity against blood-stage malaria either through
inhibition of merozoite invasion of red blood cells or antibody-mediated cell cytotoxicity
against infected red blood cells [47,48]. From this standpoint, we hypothesize that the presence
of helminths could affect the quality of the antibodies produced in response to the vaccine can-
didate, as described elsewhere [49,50], influencing their effect on P. falciparum. We speculate
that the lack of GMZ2 efficacy shown in our study may therefore at least be partly due to the
presence of helminths.
We recognize limitations to this study, notably the small number of infected individuals in
the subgroups, precluding further in-depth statistical tests. In addition, the study was
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conducted exclusively on males, precluding the extrapolation of any conclusions to the popula-
tion at large. The observational and exploratory nature of the study also means that causality
cannot be easily addressed. Furthermore, the helminth groups are not randomized and likely
differ systematically in other variables that may introduce bias. Another possible limitation is
the CHMI, since it has never been used before in this context. Additionally, the fact that not all
the available plasma at different time points were analyzed, and that the helminth diagnosis
was not made between D0 and D84, weakens the results, because it would allow to check if
these same observations are made at other time points. Despite these limitations, we did find
some relevant and significant results and we believe that our findings provide important infor-
mation on the negative effect of helminth infection on vaccine-induced protective immunity,
and a probable double impact that helminths and S. haematobium in particular, could have on
other parasites [11] or on the response to vaccine antigens. Other studies on the effect of hel-
minths in malaria vaccine candidates on larger cohorts are needed to further corroborate these
findings.
In summary, we report that the effect of helminth infection status on anti-GMZ2 immuno-
genicity could be parasite species-dependent, and that vaccine efficacy can be altered by hel-
minth infections. If confirmed in other large cohort studies, it would clearly be therefore
highly relevant to take into account volunteers’ helminth status when assessing the immunoge-
nicity and efficacy of malaria vaccine candidates. A conclusion of this understanding may be
to only include participants free of helminths, particularly in the early stages of clinical devel-
opment of vaccines in which small sample sizes are a requisite.
Supporting information
S1 Table. Oligonucleotides List for the real time amplification. BHQ: Black hole quencher
All the primers and probes were ordered by Eurofines. For the amplification we always did a
triplex.
(DOCX)
S2 Table. PCR mix optimized for our Study. Different primers and probes concentrations
were tested to evaluate the best one for our assay. We used the following primers and probes
concentration for each species: 0.1 μM, 0.2 μM, 0.3 μM and 0.4 μM. After checking and analyz-
ing the PCR amplification curves, we decided to use the 0.2 μM concentration. Table 2 shows
the chosen setting for our assay. # Volume depending of the reagent start concentration.
(DOCX)
S3 Table. Proportion of helminth species in coinfected groups at D0 and/or at D84. Infec-
tion (+) either by PCR and/or microscopy at D0 and/or at D84 No infection (-) either by PCR
and/or microscopy at D0 and/or at D84.
(DOCX)
S4 Table. Distribution of helminth species in the helminth co-infected group in individuals
who did or did not develop malaria following CHMI. The percentage of each helminth spe-
cie in the helminth coinfected group in those who did and did not develop malaria was calcu-
lated following the formula: (Number of volunteers infected at D0 and/or D84 x 100) / Total
number of volunteers who did (Malaria) or did not develop malaria (No malaria) following
CHMI.
(DOCX)
S5 Table. Schistosoma haematobium egg counts per subject in infected volunteers.
(DOCX)
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S1 Fig. Timeline of immunizations and blood sample collection I, II and III represent
respectively the first, second and the third immunization. Blood collection was done before
each immunization and at seven, fourteen days after the first and second immunization, and
seven, fourteen and twenty-eight days after the third immunization, as well as one day before
the CHMI and thirty-five day after the CHMI. The asterisk represents the time of urine and
stool collection.
(TIF)
S2 Fig. Anti-GMZ2, anti-MSP3 and anti-GLURP IgG concentrations between D0 and D84 in
vaccination groups Figures show the log of GMZ2-specific (A), MSP3-specific (B), GLURP-
specific (C) IgG concentrations at D0 (filled dot) and at D84 (unfilled dot) in participants vac-
cinated with Rabies vaccine, 100 μg GMZ2-Alhydrogel, 30 μg GMZ2-CAF01; and 100 μg
GMZ2-CAF01. The comparison was performed using a paired t-test. The graphs show
mean ± standard deviation. Statistical significance was set for p value below 0.05 �p<0.05,
��p<0.01, ���p<0.001, ����p<0.0001. NS = Non-significant.
(TIF)
S1 Data. Data underlying the findings.
(XLSX)
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Akim Adegnika.
References
1. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil
transmitted helminth infections in 2010. Parasit Vectors. 2014 Jan 21; 7:37. https://doi.org/10.1186/
1756-3305-7-37 PMID: 24447578
2. Hotez PJ, Kamath A. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, dis-
tribution, and disease burden. PLoS Negl Trop Dis. 2009 Aug 25; 3(8):e412. https://doi.org/10.1371/
journal.pntd.0000412 PMID: 19707588
3. Mutapi F, Roussilhon C, Mduluza T, Druilhe P. Anti-malaria humoral responses in children exposed to
Plasmodium falciparum and Schistosoma haematobium. Mem Inst Oswaldo Cruz. 2007 Jun; 102
(3):405–9. https://doi.org/10.1590/s0074-02762007005000046 PMID: 17568947
4. Courtin D, Djilali-Saiah A, Milet J, Soulard V, Gaye O, Migot-Nabias F, et al. Schistosoma haematobium
infection affects Plasmodium falciparum-specific IgG responses associated with protection against
malaria. Parasite Immunol. 2011 Feb; 33(2):124–31. https://doi.org/10.1111/j.1365-3024.2010.01267.x
PMID: 21226725
5. Ateba-Ngoa U, Jones S, Zinsou JF, Honkpehedji J, Adegnika AA, Agobe JC, et al. Associations
Between Helminth Infections, Plasmodium falciparum Parasite Carriage and Antibody Responses to
Sexual and Asexual Stage Malarial Antigens. Am J Trop Med Hyg. 2016 Aug; 95(2):394–400. https://
doi.org/10.4269/ajtmh.15-0703 PMID: 27273645
6. Lyke KE, Dabo A, Sangare L, Arama C, Daou M, Diarra I, et al. Effects of concomitant Schistosoma
haematobium infection on the serum cytokine levels elicited by acute Plasmodium falciparum malaria
infection in Malian children. Infect Immun. 2006 Oct; 74(10):5718–24. https://doi.org/10.1128/IAI.
01822-05 PMID: 16988248
7. Diallo TO, Remoue F, Gaayeb L, Schacht AM, Charrier N, De Clerck D, et al. Schistosomiasis coinfec-
tion in children influences acquired immune response against Plasmodium falciparum malaria antigens.
PLoS One. 2010 Sep 15; 5(9):e12764. https://doi.org/10.1371/journal.pone.0012764 PMID: 20856680
8. Spiegel A, Tall A, Raphenon G, Trape JF, Druilhe P. Increased frequency of malaria attacks in subjects
co-infected by intestinal worms and Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2003
Mar; 97(2):198–9. https://doi.org/10.1016/s0035-9203(03)90117-9 PMID: 14584377
9. Abanyie FA, McCracken C, Kirwan P, Molloy SF, Asaolu SO, Holland CV, et al. Ascaris co-infection
does not alter malaria-induced anaemia in a cohort of Nigerian preschool children. Malar J. 2013 Jan 2;
12:1. https://doi.org/10.1186/1475-2875-12-1 PMID: 23282136
10. Shapiro AE, Tukahebwa EM, Kasten J, Clarke SE, Magnussen P, Olsen A, et al. Epidemiology of hel-
minth infections and their relationship to clinical malaria in southwest Uganda. Trans R Soc Trop Med
Hyg. 2005 Jan; 99(1):18–24. https://doi.org/10.1016/j.trstmh.2004.02.006 PMID: 15550257
11. Dejon-Agobe JC, Zinsou JF, Honkpehedji YJ, Ateba-Ngoa U, Edoa JR, Adegbite BR, et al. Schisto-
soma haematobium effects on Plasmodium falciparum infection modified by soil-transmitted helminths
in school-age children living in rural areas of Gabon. PLoS Negl Trop Dis. 2018 Aug; 12(8):e0006663.
https://doi.org/10.1371/journal.pntd.0006663 PMID: 30080853
12. Bruckner S, Agnandji ST, Berberich S, Bache E, Fernandes JF, Schweiger B, et al. Effect of Antihel-
minthic Treatment on Vaccine Immunogenicity to a Seasonal Influenza Vaccine in Primary School Chil-
dren in Gabon: A Randomized Placebo-Controlled Trial. PLoS Negl Trop Dis. 2015; 9(6):e0003768.
https://doi.org/10.1371/journal.pntd.0003768 PMID: 26053679
PLOS NEGLECTED TROPICAL DISEASES Helminth affect GMZ2 malaria vaccine candidate outcome
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009361 June 1, 2021 15 / 18
13. Elias D, Akuffo H, Britton S. Helminthes could influence the outcome of vaccines against TB in the trop-
ics. Parasite Immunol. 2006 Oct; 28(10):507–13. https://doi.org/10.1111/j.1365-3024.2006.00854.x
PMID: 16965286
14. Elias D, Akuffo H, Pawlowski A, Haile M, Schon T, Britton S. Schistosoma mansoni infection reduces
the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis. Vaccine. 2005
Feb 3; 23(11):1326–34. https://doi.org/10.1016/j.vaccine.2004.09.038 PMID: 15661380
15. Elias D, Britton S, Aseffa A, Engers H, Akuffo H. Poor immunogenicity of BCG in helminth infected pop-
ulation is associated with increased in vitro TGF-beta production. Vaccine. 2008 Jul 23; 26(31):3897–
902. https://doi.org/10.1016/j.vaccine.2008.04.083 PMID: 18554755
16. Elias D, Wolday D, Akuffo H, Petros B, Bronner U, Britton S. Effect of deworming on human T cell
responses to mycobacterial antigens in helminth-exposed individuals before and after bacille Calmette-
Guerin (BCG) vaccination. Clin Exp Immunol. 2001 Feb; 123(2):219–25. https://doi.org/10.1046/j.1365-
2249.2001.01446.x PMID: 11207651
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Diagnostic Techniques of Soil-Transmitted Helminths: Impact on Control Measures. Trop Med Infect
Dis [Internet]. 2020 Jun 5; 5(2). https://doi.org/10.3390/tropicalmed5020093 PMID: 32516900
34. Akue JP, Nkoghe D, Padilla C, Moussavou G, Moukana H, Mbou RA, et al. Epidemiology of Concomi-
tant Infection Due to Loa loa and Mansonella perstans in Gabon. PLoS Negl Trop Dis [Internet]. 2011
Oct 11; 5(10). https://doi.org/10.1371/journal.pntd.0001329 PMID: 22022623
35. Kaisar MMM, Brienen EAT, Djuardi Y, Sartono E, Yazdanbakhsh M, Verweij JJ, et al. Improved diagno-
sis of Trichuris trichiura by using a bead-beating procedure on ethanol preserved stool samples prior to
DNA isolation and the performance of multiplex real-time PCR for intestinal parasites. Parasitology.
2017 Jun; 144(7):965–74. https://doi.org/10.1017/S0031182017000129 PMID: 28290266
36. Verweij JJ, Brienen EA, Ziem J, Yelifari L, Polderman AM, Van Lieshout L. Simultaneous detection and
quantification of Ancylostoma duodenale, Necator americanus, and Oesophagostomum bifurcum in
fecal samples using multiplex real-time PCR. Am J Trop Med Hyg. 2007 Oct; 77(4):685–90. PMID:
17978072
37. Verweij JJ, Canales M, Polman K, Ziem J, Brienen EA, Polderman AM, et al. Molecular diagnosis of
Strongyloides stercoralis in faecal samples using real-time PCR. Trans R Soc Trop Med Hyg. 2009 Apr;
103(4):342–6. https://doi.org/10.1016/j.trstmh.2008.12.001 PMID: 19195671
38. Liu J, Gratz J, Amour C, Kibiki G, Becker S, Janaki L, et al. A laboratory-developed TaqMan Array Card
for simultaneous detection of 19 enteropathogens. J Clin Microbiol. 2013 Feb; 51(2):472–80. https://doi.
org/10.1128/JCM.02658-12 PMID: 23175269
39. Taniuchi M, Verweij JJ, Noor Z, Sobuz SU, Lieshout L, Petri WA Jr, et al. High throughput multiplex
PCR and probe-based detection with Luminex beads for seven intestinal parasites. Am J Trop Med
Hyg. 2011 Feb; 84(2):332–7. https://doi.org/10.4269/ajtmh.2011.10-0461 PMID: 21292910
40. Adegnika AA, Ramharter M, Agnandji ST, Ateba Ngoa U, Issifou S, Yazdanbahksh M, et al. Epidemiol-
ogy of parasitic co-infections during pregnancy in Lambarene, Gabon. Trop Med Int Health. 2010 Oct;
15(10):1204–9. https://doi.org/10.1111/j.1365-3156.2010.02598.x PMID: 20636299
41. Verroust PJ, Adam C, Smith MD, Richard-Lenoble D, Kourilsky O, Morel-Maroger LJ. Circulating
immune complexes and C3d in human parasitosis. Kidney Int. 1979 Jul; 16(1):9–14. https://doi.org/10.
1038/ki.1979.97 PMID: 575177
42. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular
adjuvant: bridging innate and acquired immunity. Science. 1996 Jan 19; 271(5247):348–50. https://doi.
org/10.1126/science.271.5247.348 PMID: 8553069
43. Luoni G, Verra F, Arca B, Sirima BS, Troye-Blomberg M, Coluzzi M, et al. Antimalarial antibody levels
and IL4 polymorphism in the Fulani of West Africa. Genes Immun. 2001 Nov; 2(7):411–4. https://doi.
org/10.1038/sj.gene.6363797 PMID: 11704810
44. Tokplonou L, Nouatin O, Sonon P, M’po G, Glitho S, Agniwo P, et al. Schistosoma haematobium infec-
tion modulates Plasmodium falciparum parasite density and antimalarial antibody responses. Parasite
Immunol. 2020 Feb 5;e12702. https://doi.org/10.1111/pim.12702 PMID: 32020650
45. Anuradha R, Munisankar S, Bhootra Y, Dolla C, Kumaran P, Nutman TB, et al. Modulation of Mycobac-
terium tuberculosis-specific humoral immune responses is associated with Strongyloides stercoralis co-
infection. PLoS Negl Trop Dis. 2017 May; 11(5):e0005569. https://doi.org/10.1371/journal.pntd.
0005569 PMID: 28459817
46. Iriemenam NC, Sanyaolu AO, Oyibo WA, Fagbenro-Beyioku AF. Strongyloides stercoralis and the
immune response. Parasitol Int. 2010 Mar; 59(1):9–14. https://doi.org/10.1016/j.parint.2009.10.009
PMID: 19892034
47. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that
protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth
and invasion in vitro, but act in cooperation with monocytes. J Exp Med. 1990 Dec 1; 172(6):1633–41.
https://doi.org/10.1084/jem.172.6.1633 PMID: 2258697
48. O’Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, et al. Antibodies
against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory
PLOS NEGLECTED TROPICAL DISEASES Helminth affect GMZ2 malaria vaccine candidate outcome
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009361 June 1, 2021 17 / 18
response in individuals immune to malaria. J Exp Med. 2001 Jun 18; 193(12):1403–12. https://doi.org/
10.1084/jem.193.12.1403 PMID: 11413195
49. Druilhe P, Tall A, Sokhna C. Worms can worsen malaria: towards a new means to roll back malaria?
Trends Parasitol. 2005 Aug; 21(8):359–62. https://doi.org/10.1016/j.pt.2005.06.011 PMID: 15967721
50. Roussilhon C, Brasseur P, Agnamey P, Perignon JL, Druilhe P. Understanding human-Plasmodium fal-
ciparum immune interactions uncovers the immunological role of worms. PLoS One. 2010 Feb 19; 5(2):
e9309. https://doi.org/10.1371/journal.pone.0009309 PMID: 20174576
PLOS NEGLECTED TROPICAL DISEASES Helminth affect GMZ2 malaria vaccine candidate outcome
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009361 June 1, 2021 18 / 18
